Browse Category

Financial Analysis News 30 December 2025

Upwork stock drops 3% today as UPWK slips below $20 with earnings ahead

Upwork stock drops 3% today as UPWK slips below $20 with earnings ahead

NEW YORK, December 30, 2025, 15:28 ET — Regular session Upwork Inc shares were last down 3.4% at $19.60 on Tuesday, after dipping as low as $19.60 in the session. The stock, valued at about $2.46 billion, was sliding even as the S&P 500 and Nasdaq-100 proxies were only modestly lower. The move matters because Upwork has been trading as a profitability-and-execution story, leaving the stock prone to sharp swings when investors rotate away from smaller growth names. A fall below the $20 level also puts a spotlight on near-term technical support, with traders watching whether the stock can reclaim
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

NEW YORK, December 30, 2025, 15:14 ET — Regular session Shares of TIC Solutions, Inc. (TIC) fell about 3.5% to $10.02 in afternoon trading on Tuesday, underperforming a largely steady U.S. equity market. The stock last closed at $10.38. The decline came in holiday-thin trade as investors recalibrated rate expectations after the Federal Reserve’s December-meeting minutes hit the tape. “At the end of the day, solid corporate profits can make up for a lot of sins,” said Ryan Detrick, chief market strategist at Carson Group. Reuters The slide matters for TIC because investors have been focused on execution rather than
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

NEW YORK, December 30, 2025, 2:30 PM ET — Regular session Shares of Catalyst Pharmaceuticals, Inc. fell 3.0% to $23.33 in afternoon trading on Tuesday. The stock has traded between $23.30 and $24.10 so far in the session. The drop matters because trading can get choppy in the final days of the year, when fewer investors are active and price moves can be exaggerated. Mid-cap healthcare names often swing more than the major indexes in that setting. Catalyst fell 1.2% on Monday to close at $24.06, according to MarketWatch data, and it remains well below its June 9 52-week high
Nebius stock slips today after CEO files to sell shares — what traders are watching next

Nebius stock slips today after CEO files to sell shares — what traders are watching next

NEW YORK, December 30, 2025, 15:09 ET — Regular session Nebius Group N.V. shares slipped on Tuesday after a regulatory filing showed chief executive Arkady Volozh plans to sell a small block of stock around year-end. SEC+1 The disclosure matters because Nebius has become a closely watched AI infrastructure name, where investors have been quick to react to any potential increase in share supply. Year-end trading can amplify moves, as fewer shares changing hands can push prices around. SEC Form 144 is the SEC notice insiders file when they intend to sell “control” securities, typically ahead of the actual transactions.
Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

NEW YORK, December 30, 2025, 14:44 ET — Regular session Texas Instruments Incorporated (TXN) shares were little changed on Tuesday after memory developer Weebit Nano said it had licensed its resistive random access memory, or ReRAM, technology to the chipmaker. The stock was down about 0.01% at $175.67 in afternoon trade, and TI executive Amichai Ron said the partnership would give customers access to “industry-leading NVM technology.” Weebit The announcement matters because embedded non-volatile memory — storage that keeps data when power is off — is a key building block for chips that run cars, factory equipment and other electronics
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

NEW YORK, December 30, 2025, 14:35 ET — Regular session AT&T Inc shares were up 0.1% at $24.80 in afternoon trade on Tuesday, hovering near the top of a tight day range as the broader market struggled for direction. The stock traded between $24.75 and $24.85. The move matters because income-heavy telecom stocks often trade with interest-rate expectations at year-end, when many investors rebalance portfolios. The yield on the 10-year U.S. Treasury note rose 1.8 basis points — a basis point is 0.01 percentage point — to 4.134%, and traders were awaiting the Federal Reserve’s meeting minutes later in the
PayPal stock slips in late trade after Fed minutes; here’s what PYPL investors are watching next

PayPal stock slips in late trade after Fed minutes; here’s what PYPL investors are watching next

NEW YORK, December 30, 2025, 14:33 ET — Regular session PayPal Holdings (PYPL.O) shares were down about 0.6% at $59.14 in afternoon trading on Tuesday, after the Federal Reserve’s latest meeting minutes sharpened the debate over where interest rates go next. The move matters because liquidity is thin into year-end, when smaller trades can have an outsized impact on price. For consumer-facing fintech names like PayPal, rate expectations and spending signals can quickly swing sentiment. Investors are also recalibrating for 2026 after fresh color from the Fed on how comfortable policymakers are with further easing. The minutes are a detailed
CRH stock dips today as buyback rolls on and Fed minutes loom

CRH stock dips today as buyback rolls on and Fed minutes loom

NEW YORK, December 30, 2025, 14:02 ET — Regular session Shares of CRH plc (CRH) fell about 1.1% to $126.01 in afternoon New York trading on Tuesday after the building materials group disclosed another day of repurchases under its U.S. buyback program. CRH said it bought 31,100 shares on Monday at a volume-weighted average price of $127.33, paying between $126.46 and $128.87, and will cancel the shares as part of a plan to repurchase up to $300 million of stock by Feb. 17. The stock traded between $125.92 and $127.25 on Tuesday. Business Wire The move matters now because CRH
ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

NEW YORK, December 30, 2025, 13:35 ET — Regular session Shares of ADMA Biologics fell 3.7% to $18.40 in afternoon trading on Tuesday, a steeper drop than the broader biotech group. The SPDR S&P Biotech ETF was down about 1.3%. The pullback came as U.S. stocks steadied in holiday-thin trading ahead of minutes from the Federal Reserve’s December policy meeting, after the central bank delivered a 25-basis-point cut this month. Mark Hackett, chief market strategist at Nationwide, described recent positioning as “a healthy rebalancing of allocations.” Reuters Biotechnology shares were among the laggards, with the NYSE Arca Biotechnology Index down
Rivian stock drops nearly 6% as CEO share-sale filing hits the tape in thin year-end trade

Rivian stock drops nearly 6% as CEO share-sale filing hits the tape in thin year-end trade

NEW YORK, December 30, 2025, 13:30 ET — Regular session Rivian Automotive, Inc shares were down about 6% on Tuesday, pulling back in a light year-end session after a regulatory filing disclosed a stock sale by Chief Executive Officer Robert J. Scaringe. The move matters because thin holiday liquidity can exaggerate swings in high-volatility names, and investors have shifted back to demand signals and funding risk across electric-vehicle makers. Traders also had one eye on U.S. Federal Reserve minutes due later in the session and a closely watched Tesla update on quarterly deliveries, events that can reset risk appetite for
Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

NEW YORK, December 30, 2025, 13:34 ET — Regular session Warby Parker Inc (WRBY) shares fell about 3.9% to $22.11 in early afternoon trading on Tuesday, after ending Monday at $23.00. The stock opened at $22.90 and traded between $21.87 and $23.13, with nearly 3 million shares changing hands; the company is valued at about $3.4 billion. The slide comes with just a handful of sessions left in 2025, a stretch when trading often thins out and price moves can look outsized. Thin trading means fewer buyers and sellers, so routine position changes can move a stock more than usual.
1 140 141 142 143 144 287

Stock Market Today

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop